Skip to main content
OpenTrials
Completed

NCT Number: NCT01085474

Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient

Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Madrid, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have given their informed consent and expressed interest in participating in the study
  • Asthmatic Patients

Exclusion criteria

  • Patients with communication difficulties.
  • Persons who obtain symbicort but not for their own use.
  • Patients with other major diseases: Heart problems, COPD, EMPHYSEMA, lung cancer, AIDS.
  • Patients with a respiratory infection.
  • Patients with seasonal asthma.
  • Pregnant women
  • Patients who have previously participated in a health education study in asthma.

Treatment and study plan

1

Other

In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.

2

Other

The best intervention used in the pilot study will be chosen and included in the main study.

Primary outcomes

  1. Evaluate the effect of the pharmaceutical intervention on the disease control, treatment adherence and patient knowledge of his/her medication using the MEF, treatment adherence and patient knowledge of the medication indicators.

    Time frame: First a Pilot in 3 months and then the final study in 6 months

Secondary outcomes

  1. Compare disease control in patients who know their medication and those who doesn't.

    Time frame: First a Pilot in 3 months and then the final study in 6 months

  2. Compare disease control in patients who comply with their medication with those who doesn't.

    Time frame: First a Pilot in 3 months and then the final study in 6 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Mar 12, 2010
Registry last updated
Jan 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.